Bank of America’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bank of America’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-162,000	Closed	-$9.52M	–	8388
2023 Q4	$9.52M	Buy	+162,000	New	+$9.11M	﹤0.01%	2941
2022 Q4	–	Sell	-400,000	Closed	-$27.9M	–	8522
2022 Q3	$27.9M	Buy	+400,000	New	+$29.6M	﹤0.01%	1690
2022 Q2	–	Sell	-13,300	Closed	-$1.09M	–	8566
2022 Q1	$1.09M	Buy	+13,300	New	+$1.36M	﹤0.01%	5143
2021 Q4	–	Sell	-800	Closed	-$142K	–	8808
2021 Q3	$142K	Sell	800 -400	-33%	-$64.4K	﹤0.01%	6522
2021 Q2	$194K	Buy	+1,200	New	+$193K	﹤0.01%	6122
2019 Q1	–	Sell	-25,000	Closed	-$1.06M	–	7493
2018 Q4	$1.06M	Hold	25,000	–	–	﹤0.01%	4358
2018 Q3	$1.18M	Sell	25,000 -25,000	-50%	-$1.39M	﹤0.01%	4374
2018 Q2	$2.46M	Buy	+50,000	New	+$1.89M	﹤0.01%	3813

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bank of America's MRTX Position: Q1 2024 in Review

Bank of America sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 36,000 shares — an estimated $2.11M sold.

Bank of America first reported a position in MRTX in Q2 2014 and held it in 37 quarters. The position peaked at $35.1M in Q2 2021. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

Bank of America reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Bank of America sold 36,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.11M.
Bank of America first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2014 and held it in 37 quarters.
Bank of America's Mirati Therapeutics, Inc. Common Stock position peaked at $35.1M in Q2 2021.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Bank of America's 13F filing for Q1 2024, filed 15 May 2024.